PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Midazolam and Darunavir Interaction

Drug interaction information between Midazolam and Darunavir.

Midazolam and Darunavir have a documented major interaction in FDA labeling.

FDA drug labeling documents a major-severity interaction between Midazolam and Darunavir. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.

Drug A

Midazolam

Benzodiazepine

Drug B

Darunavir

HIV Protease Inhibitor

How They Interact

Darunavir blocks the enzyme that breaks down midazolam, causing the sedative to build up in your body. This can lead to dangerously deep sleep or breathing problems.

What To Do

You should not take these two medicines together because the combination can be life-threatening.

FDA Label Information

Sedatives/hypnotics: orally administered midazolam, triazolam ↑ midazolam ↑ triazolam Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression. Triazolam and orally administered midazolam are extensively metabolized by CYP3A. Co-administration of triazolam or orally administered midazolam with darunavir may cause large increases in the concentrations of these benzodiazepines.

Frequently Asked Questions

Can I take Midazolam and Darunavir together?

This is a major interaction. You should not take these two medicines together because the combination can be life-threatening.

How serious is the interaction between Midazolam and Darunavir?

This interaction is classified as "major" severity by the FDA. Major interactions may be life-threatening or cause serious side effects.

Why do Midazolam and Darunavir interact?

Darunavir blocks the enzyme that breaks down midazolam, causing the sedative to build up in your body. This can lead to dangerously deep sleep or breathing problems.

Understanding the Midazolam and Darunavir Interaction

FDA-approved prescribing information for these two drugs flags their combination as a major-severity interaction. Midazolam belongs to the Benzodiazepine class and Darunavir belongs to the HIV Protease Inhibitor class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Darunavir blocks the enzyme that breaks down midazolam, causing the sedative to build up in your body. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Midazolam has 39 total documented interactions on file in this dataset, and Darunavir has 101. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: You should not take these two medicines together because the combination can be life-threatening. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Midazolam or Darunavir based on a web page, speak with your prescriber or pharmacist before making any change.

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.